Novo and Sanofi Ventures both participated in a series A round for the neurodegenrative disease drug developer, which is led by EIRs at Novo Seeds.

Muna Therapeutics, a Denmark-based developer of treatments for neurodegenerative diseases, closed a $73m series A round today backed by pharmaceutical firms Novo and Sanofi.

Sofinnova Partners, Droia Ventures and LSP Dementia co-led the round, which included research institute VIB and its venture capital affiliate V-Bio Ventures, Polaris Partners and Polaris Innovation Fund, while Sanofi took part through strategic investment arm Sanofi Ventures.

Muna is focusing on neurodegenerative diseases for which no cure is currently available and for which palliative care…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn